NAMs Expansion VivoSim Labs is actively expanding its NAMkind liver platform with a rat liver model to complement human liver models, signaling growth in preclinical tox and efficacy testing services that can be pitched to pharma clients seeking cross-species validation and more comprehensive safety profiles.

Global Market Reach The company has begun commercial sales in China and continues to broaden its geographic footprint, presenting a ready opportunity to engage regional pharma networks, CROs, and biotechs seeking NAM-based testing capabilities in high-growth Asian markets.

AI Prediction Tool An available AI tool for predicting drug-induced diarrhea using NAMkind intestinal models demonstrates a tangible differentiator for safety screening, offering a compelling upsell for early-stage programs that require rapid, cost-efficient risk assessment.

3D Bioprinting Expertise Specialized 3D bioprinted human-relevant tissue models position VivoSim as a strategic partner for companies focused on better translational accuracy, enabling collaborative drug profiling deals, bespoke model development, and high-value safety pharmacology studies.

Strategic Partnerships Recent awards and industry recognition for NAMkind solutions, along with a sizable funding base, create opportunities to approach pharma and biotech investors or strategic buyers seeking validated, scalable NAM-enabled pipelines and clinical translation potential.